Rifaximin Use in Hepatic Encephalopathy – Guideline Summary

1. Indications for Rifaximin

Secondary prophylaxis only: Rifaximin is recommended solely for patients who have experienced at least one documented episode of overt hepatic encephalopathy (HE); it is not indicated for primary prevention. American Association for the Study of Liver Diseases (AASLD) guideline – strong recommendation. 1
After the first overt HE episode: Initiate lactulose alone as secondary prophylaxis, titrating to achieve 2–3 soft bowel movements daily. AASLD guideline – strong recommendation. 1
After a second overt HE episode within 6 months: Add rifaximin 550 mg twice daily to ongoing lactulose therapy. AASLD guideline – strong recommendation. 1
Pre‑TIPS prophylaxis: In patients with a prior overt HE episode who are scheduled for elective transjugular intra‑hepatic portosystemic shunt (TIPS), rifaximin may be started 14 days before the procedure. AASLD guideline – conditional recommendation. 3

Screen for precipitating factors: Systematically evaluate infection, constipation, gastrointestinal bleeding, dehydration, electrolyte disturbances, renal dysfunction, and use of psycho‑active medications. AASLD guideline – strong recommendation. 4
Nutritional optimization: Provide protein 1.2–1.5 g/kg/day and calories 35–40 kcal/kg/day to prevent sarcopenia, a known risk factor for HE. AASLD guideline – strong recommendation. 4
Avoid protein restriction: Long‑term protein restriction leads to catabolism and worsens clinical outcomes; it should not be employed. AASLD guideline – strong recommendation. 4

Routine ammonia measurement is not recommended for diagnosing or managing HE when clinical encephalopathy is absent. AASLD guideline – weak recommendation. 7
Interpretation limits: Ammonia levels vary widely between patients and laboratories and may be elevated in non‑HE conditions; therefore, an isolated elevated value does not dictate therapy. AASLD guideline – weak recommendation. 7

Initiation for overt HE (West Haven grade ≥ 2): Begin lactulose 30–45 mL every 1–2 hours until the patient achieves 2–3 soft bowel movements daily. AASLD guideline – strong recommendation. 2
Severe HE (grade ≥ 3) or inability to take oral medication: Use lactulose enemas (300 mL lactulose diluted in 700 mL water). AASLD guideline – strong recommendation. 2
Maintenance: Continue lactulose indefinitely after the first overt episode, adjusting dose (≈20–30 g, 3–4 times daily) to maintain the target stool frequency. AASLD guideline – strong recommendation. 1

No high‑quality evidence supports primary prevention of HE with rifaximin in patients who have never had overt HE. AASLD guideline – strong recommendation against use. 1
Secondary‑prevention trial data: In the pivotal randomized controlled trial, rifaximin (plus lactulose) reduced breakthrough HE from 45.9 % to 22.1 % over 6 months in patients already in remission from recurrent HE. AASLD guideline – high‑quality evidence. (Citation excluded because the original reference was marked “ignore ref”; the guideline statement is still reflected in @1.)

Unnecessary costs and adverse effects: Starting rifaximin before the established indication provides no proven benefit and exposes patients to potential side effects and increased medication expense. AASLD guideline – strong recommendation to avoid premature use. 1

Prognosis after overt HE: Survival after a first overt HE episode is approximately 42 % at 1 year and 23 % at 3 years. AASLD guideline – moderate‑quality evidence. 2
Early transplant referral: Decompensation, including overt HE, should trigger prompt referral to a liver transplant center. AASLD guideline – strong recommendation. 7
Indication for transplantation: Recurrent or persistent HE despite optimal medical therapy (lactulose ± rifaximin) is an accepted indication for liver transplantation. AASLD guideline – strong recommendation. 1